Omega Therapeutics Analyst Ratings
Omega Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/13/2023 | 640.74% | HC Wainwright & Co. | $11 → $12 | Maintains | Buy |
| 11/10/2023 | 640.74% | Wedbush | $19 → $12 | Maintains | Outperform |
| 09/01/2023 | 579.01% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 08/04/2023 | 640.74% | Chardan Capital | → $12 | Reiterates | Buy → Buy |
| 06/06/2023 | 579.01% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 05/08/2023 | 640.74% | Chardan Capital | → $12 | Reiterates | → Buy |
| 03/31/2023 | 579.01% | HC Wainwright & Co. | → $11 | Reiterates | → Buy |
| 03/24/2023 | 579.01% | HC Wainwright & Co. | → $11 | Reiterates | → Buy |
| 03/10/2023 | 579.01% | JonesTrading | → $11 | Initiates Coverage On | → Buy |
| 03/03/2023 | 517.28% | Piper Sandler | $8 → $10 | Maintains | Overweight |
| 12/08/2022 | 579.01% | HC Wainwright & Co. | → $11 | Initiates Coverage On | → Buy |
| 09/23/2022 | 640.74% | Chardan Capital | → $12 | Initiates Coverage On | → Buy |
| 05/24/2022 | 146.91% | Goldman Sachs | $7 → $4 | Maintains | Neutral |
| 05/23/2022 | 332.1% | Piper Sandler | $30 → $7 | Maintains | Overweight |
| 08/24/2021 | 2122.22% | Wedbush | → $36 | Initiates Coverage On | → Outperform |
| 08/24/2021 | 1751.85% | Jefferies | → $30 | Initiates Coverage On | → Buy |
| 08/24/2021 | 1751.85% | Piper Sandler | → $30 | Initiates Coverage On | → Overweight |
| 08/24/2021 | 1258.02% | Goldman Sachs | → $22 | Initiates Coverage On | → Neutral |
| 日期 | 上行/下行 | 分析師事務所 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/13/2023 | 640.74% | HC Wainwright & Co. | 11 美元 → 12 美元 | 維護 | 購買 |
| 11/10/2023 | 640.74% | Wedbush | 19 美元 → 12 美元 | 維護 | 跑贏大盤 |
| 09/01/2023 | 579.01% | HC Wainwright & Co. | → 11 美元 | 重申 | 購買 → 購買 |
| 08/04/2023 | 640.74% | 查丹資本 | → 12 美元 | 重申 | 購買 → 購買 |
| 06/06/2023 | 579.01% | HC Wainwright & Co. | → 11 美元 | 重申 | 購買 → 購買 |
| 05/08/2023 | 640.74% | 查丹資本 | → 12 美元 | 重申 | → 購買 |
| 03/31/2023 | 579.01% | HC Wainwright & Co. | → 11 美元 | 重申 | → 購買 |
| 2023 年 3 月 24 日 | 579.01% | HC Wainwright & Co. | → 11 美元 | 重申 | → 購買 |
| 03/10/2023 | 579.01% | JonesTrading | → 11 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 03/03/2023 | 517.28% | 派珀·桑德勒 | 8 美元 → 10 美元 | 維護 | 超重 |
| 2022 年 8 月 12 日 | 579.01% | HC Wainwright & Co. | → 11 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 09/23/2022 | 640.74% | 查丹資本 | → 12 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2022 年 5 月 24 日 | 146.91% | 高盛 | 7 美元 → 4 美元 | 維護 | 中立 |
| 05/23/2022 | 332.1% | 派珀·桑德勒 | 30 美元 → 7 美元 | 維護 | 超重 |
| 08/24/2021 | 2122.22% | Wedbush | → 36 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 08/24/2021 | 1751.85% | 傑富瑞集團 | → 30 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/24/2021 | 1751.85% | 派珀·桑德勒 | → 30 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 08/24/2021 | 1258.02% | 高盛 | → 22 美元 | 啓動覆蓋範圍開啓 | → 中立 |
What is the target price for Omega Therapeutics (OMGA)?
歐米茄療法（OMGA）的目標價格是多少？
The latest price target for Omega Therapeutics (NASDAQ: OMGA) was reported by HC Wainwright & Co. on November 13, 2023. The analyst firm set a price target for $12.00 expecting OMGA to rise to within 12 months (a possible 640.74% upside). 11 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月13日公佈了歐米茄療法（納斯達克股票代碼：OMGA）的最新目標股價。該分析公司將目標股價設定爲12.00美元，預計OMGA將在12個月內上漲至12美元（可能上漲640.74％）。去年有11家分析公司公佈了評級。
What is the most recent analyst rating for Omega Therapeutics (OMGA)?
歐米茄療法（OMGA）的最新分析師評級是多少？
The latest analyst rating for Omega Therapeutics (NASDAQ: OMGA) was provided by HC Wainwright & Co., and Omega Therapeutics maintained their buy rating.
歐米茄療法（納斯達克股票代碼：OMGA）的最新分析師評級由HC Wainwright & Co. 提供，歐米茄療法維持買入評級。
When is the next analyst rating going to be posted or updated for Omega Therapeutics (OMGA)?
歐米茄療法（OMGA）的下一個分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Omega Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Omega Therapeutics was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與歐米茄療法的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。歐米茄療法的最後一次評級是在2023年11月13日公佈的，因此您應該預計下一個評級將在2024年11月13日左右公佈。
Is the Analyst Rating Omega Therapeutics (OMGA) correct?
分析師對歐米茄療法（OMGA）的評級是否正確？
While ratings are subjective and will change, the latest Omega Therapeutics (OMGA) rating was a maintained with a price target of $11.00 to $12.00. The current price Omega Therapeutics (OMGA) is trading at is $1.62, which is out of the analyst's predicted range.
儘管評級是主觀的，並將發生變化，但最新的歐米茄療法（OMGA）評級維持不變，目標股價爲11.00美元至12.00美元。歐米茄療法（OMGA）目前的交易價格爲1.62美元，超出了分析師的預期區間。